Needham & Company Reiterates Buy on Nps Pharmaceuticals Incorporated (NPSP)

By admin | 6 years ago

Nps Pharmaceuticals Incorporated (NASDAQ: NPSP)‘s stock had its “buy” rating reaffirmed by Needham & Company in a research note issued on Friday.

Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Nps Pharmaceuticals Incorporated in a research note to investors on Thursday, February 16th.

Nps Pharmaceuticals Incorporated traded down 1.69% on Friday, hitting $6.99. Nps Pharmaceuticals Incorporated has a 1-year low of $4.35 and a 1-year high of $10.75. The company’s market cap is $602.2 million.

Nps Pharmaceuticals Incorporated last issued its quarterly earnings data on Thursday, May 3rd. The company reported ($0.12) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.01. Nps Pharmaceuticals Incorporated’s revenue was down 3.0% compared to the same quarter last year. On average, analysts predict that Nps Pharmaceuticals Incorporated will post $-0.07 earnings per share next quarter.

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on the development of new treatment options for patients with gastrointestinal and endocrine disorders and medical needs.

About the author